SCHEMBL7142247

SCHEMBL7142247

Cc1ccc(S(=O)(=O)N(c2ccccc2)C2CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.52
OPRM1 P35372 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
LMNA P02545 2/20 0.50
CD4 P01730 2/20 0.50
SORT1 Q99523 1/20 0.50
POLB P06746 1/20 0.50
ALDH1A1 P00352 2/20 0.49
TSHR P16473 1/20 0.49
CHRM2 P08172 4/20 0.49
CHRM3 P20309 4/20 0.49
ACHE P22303 2/20 0.49
BACE1 P56817 2/20 0.49
CXCR4 P61073 2/20 0.49
ESR1 P03372 1/20 0.49
HTR2A P28223 1/20 0.49
HRH1 P35367 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7147151 0.91 HTR2A (0.58) OPRM1SIGMAR1CHRM2CHRM3ACHE
SCHEMBL7166030 0.90 CHRM2 (0.57) NPSR1OPRM1SIGMAR1LMNAALDH1A1
SCHEMBL7141415 0.89 CHRM4 (0.54) OPRM1SIGMAR1CHRM2CHRM3CXCR4
SCHEMBL7140154 0.89 HTT (0.58) OPRM1SIGMAR1ALDH1A1CHRM2CHRM3
SCHEMBL7145371 0.88 ALDH1A1 (0.54) NPSR1SMN1; SMN2LMNAALDH1A1TSHR
SCHEMBL7198828 0.87 BCHE (0.50) NPSR1SMN1; SMN2LMNACHRM2CHRM3
SCHEMBL7141686 0.85 CHRM2 (0.61) OPRM1SIGMAR1LMNAALDH1A1TSHR
SCHEMBL7251853 0.84 CHRM3 (0.45) OPRM1CHRM2CHRM3ACHEBACE1
SCHEMBL7166368 0.83 ALDH1A1 (0.52) NPSR1SIGMAR1LMNAALDH1A1TSHR
SCHEMBL7142524 0.83 CHRM2 (0.49) OPRM1SIGMAR1ALDH1A1TSHRCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP claimed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 NPSR1 229/4885SMN1; SMN2 2611/4885OPRM1 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.